Self reported physical activity not significantly different across different severities of hemophilia
1. In this cohort of individuals with hemophilia, the physical activity levels and step count did not significantly differ between ...
Tag: hematology
2 Minute Medicine Rewind March 31, 2025
Suicide risk and living alone with depression or anxiety 1. In this cohort of adults living in South Korea, individuals ...
Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes
1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well ...
Adjunctive middle meningeal artery embolization superior to standard care in symptomatic chronic subdural hematomas
1. In this randomized controlled trial, middle meningeal artery embolization demonstrated a decreased risk of treatment failure in patients with ...
CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma
1. This study describes two cases of malignant monoclonal T-cell lymphoproliferation following ciltacabtagene autoleucel (cilta-cel) Chimeric Antigen Receptor T-cell (CAR ...
Beti-cel gene therapy achieves high rates of transfusion independence in severe β-thalassemia
1. 89% of patients achieved transfusion independence with beti-cel gene therapy. 2. There were no serious adverse events or treatment-related ...
Intra-arterial tenecteplase has limited use after successful endovascular recanalisation of acute posterior circulation arterial occlusion
1. In patients with acute ischemic stroke due to acute intracranial occlusions of the posterior circulation, the use of intra-arterial ...
2 Minute Medicine Rewind January 13, 2025
Association of varicose veins with the risk of heart failure: A nationwide cohort study 1. Patients with varicose veins had ...
Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory ...
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible ...